… In this study, a phase Ib investigation of a cohort of patients … of cixutumumab in combination
with erlotinib and gemcitabine … to show a major impact on the natural history of this disease.2 …

… Methods: This was a phase I/randomized phase II (RP2) study testing the anti-IGF-1R
monoclonal antibody cixutumumab combined with erlotinib and G in patients with metastatic PAC. …

… IGF-1R and epidermal growth factor receptor (EGFR) mediates … -1R signaling enhanced the
antitumor effect of gemcitabine … for phase I and II enrolled pancreatic cancer patients (N = 75) …

… monoclonal antibodies such as cixutumumab (IMC-A12), AMG… When given in combination
with gemcitabine and cisplatin, … to paclitaxel plus carboplatin (ADVIGO 1016) 118 or erlotinib (…

… of erlotinib in combination with gemcitabine for the first-line treatment of patients with locally
advanced and metastatic pancreatic carcinoma [… and continuous signalling is required for its …

… Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is … Metastatic pancreatic cancer
remains a leading cause of … effectively inhibit growth factor–mediated prosurvival signaling. We …

… cell lung cancer (NSCLC)], and another with erlotinib (second … with gemcitabine in 825
patients with stage IV pancreatic cancer. … trial in 135 patients with locally advanced or metastatic …

… [69], but addition of cixutumumab to erlotinib and GEM did not lead … completed a phase I trial
for treatment of metastatic cancer, … in a phase 3 study of gemcitabine and erlotinib therapy in …

… A phase II trial compared the combination of gemcitabine, erlotinib and cixutumumab, a
monoclonal anti-insulin-like … in the treatment of metastatic pancreatic cancer. The results of a …

… Type I insulin-like growth factor receptor (IGF-1R) has long … A phase 2 trial of cixutumumab
in 31 patients with metastatic … when cixutumumab was added to gemcitabine and erlotinib as …